RxDoctor Payments Data

Melissa Todd, APRN

Nurse Practitioner · Lexington, KYNPI 1821471079

Payments from drug & device makers

$1,092in general payments, 2019–2025

Across 34 payments — averaging $32.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$277
  • Bayer$188
  • Gilead$152
  • Boehringer Ingelheim$120
  • Abbott$119
  • AstraZeneca$81
  • plus $155 from 5 others

What the payments were for

  • Food & beverage$1,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk8$277
Bayer5$188
Gilead8$152
Boehringer Ingelheim1$120
Abbott1$119
AstraZeneca3$81
Lilly USA, LLC3$49
AbbVie2$44
Novartis1$25
Madrigal Pharmaceuticals1$21
Vyera Pharmaceuticals, LLC1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,092 in reported general payments places this provider in the 70th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$75,429
Medicare patients
273
Services billed
3,244

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$102,862
EliquisApixaban91$92,822
JardianceEmpagliflozin53$57,881
JanuviaSitagliptin Phosphate36$43,266
XareltoRivaroxaban21$31,519
LinzessLinaclotide32$26,561
TrulicityDulaglutide15$22,522
MounjaroTirzepatide17$19,867
MyrbetriqMirabegron15$12,108
Tresiba Flextouch U-100Insulin Degludec12$8,421
ShingrixVaricella-Zoster Ge/As01b/Pf28$6,343
Lantus SolostarInsulin Glargine,hum.Rec.Anlog35$5,879
PremarinEstrogens, Conjugated25$5,540
Dexlansoprazole DrDexlansoprazole27$5,087
SynthroidLevothyroxine Sodium85$4,374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$277$102,862109 claims
Boehringer IngelheimJardiance$120$57,88153 claims
Lilly USA, LLCTrulicity, Mounjaro$49$42,38932 claims
AbbVieLinzess, Synthroid$44$30,935117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →